China Botanic Pharmaceutical Inc. (CBPI) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
China Botanic Pharmaceutical Inc. (CBPI) trades at $0.068. China Botanic Pharmaceutical Inc. is a shell company based in New York, actively seeking acquisition opportunities within the United States. Sector: Financial services.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for CBPI: CBPI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CBPI against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on CBPI.
How is this calculated? →China Botanic Pharmaceutical Inc. (CBPI) Financial Services Profile
China Botanic Pharmaceutical Inc., a shell company incorporated in 1988, is based in New York and focused on identifying and acquiring operating entities within the United States through reverse mergers or asset purchases. Currently without significant operations, the company presents a high-risk, high-reward scenario for speculative investors.
What Is the Investment Thesis for CBPI?
Investing in China Botanic Pharmaceutical Inc. (CBPI) is a highly speculative venture due to its shell company status and lack of current operations. The potential upside lies in the company's ability to identify and acquire a viable operating entity, which could lead to a significant increase in its stock value. However, this is contingent on several factors, including the availability of suitable acquisition targets, the company's ability to secure financing for acquisitions, and the successful integration of the acquired entity. With a negative P/E ratio of -14.50 and a high beta of 2.96, CBPI presents a high-risk, high-reward scenario for investors with a high-risk tolerance. The company's success depends entirely on its ability to execute its acquisition strategy effectively.
Based on FMP financials and quantitative analysis
CBPI Key Highlights
China Botanic Pharmaceutical Inc. operates as a shell company, lacking significant ongoing business operations.
- The company's primary objective is to identify and acquire an operating entity within the United States.
- CBPI's strategy involves exploring opportunities such as reverse mergers and asset purchases.
- The company's financial performance is currently characterized by a negative P/E ratio of -14.50.
- CBPI exhibits a high beta of 2.96, indicating significant volatility relative to the market.
Who Are CBPI's Competitors?
CBPI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AVFCF ADVFN Plc | $0.27 | +0.00% | $12.5M | 45 |
| ECGR Bellatora Inc. | $0.80 | +17.65% | $13.4M | 49 |
| GTVI Joway Health Industries Group Inc. | $0.07 | +4.43% | $15.3M | 44 |
| KBPH Kyto Technology and Life Science, Inc. | $1.00 | -45.65% | $13.3M | 38 |
| LWLW Longwen Group Corp. | $0.10 | +0.00% | $8.09M | 56 |
| AGGI Allied Energy, Inc. | $2.25 | +32.24% | $45.4B | 61 |
| GSHN Gushen, Inc. | $22.70 | +2.71% | $9.32B | 61 |
| IVAN Ivanhoe Capital Acquisition Corp. | $7.68 | -2.17% | $2.69B | 64 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CBPI's Key Strengths?
Existing corporate structure facilitates acquisitions.
- Publicly traded status provides access to capital markets.
- Established history as a corporate entity.
- Flexibility to pursue various acquisition strategies.
What Are CBPI's Weaknesses?
Lack of current operations and revenue generation.
- Dependence on identifying and acquiring a suitable target.
- High degree of uncertainty and speculative nature.
- Limited financial resources.
What Could Drive CBPI Stock Higher?
CBPI catalyst: Announcement of a potential acquisition target, which could drive investor interest and increase the stock price.
- Progress in negotiations with potential acquisition targets, indicating the company's commitment to executing its strategy.
- Changes in market conditions or regulatory environment that favor shell company acquisitions.
What Are the Key Risks for CBPI?
Failure to identify and acquire a suitable target, which could lead to a decline in the stock price.
- Competition from other shell companies and SPACs for attractive acquisition targets.
- Economic downturn or market volatility that could negatively impact acquisition activities.
- Limited financial resources and dependence on external funding for acquisitions.
- The 'Shell Risk' detected indicates a high probability of risks associated with shell companies, including fraud, lack of transparency, and potential delisting.
What Are the Growth Opportunities for CBPI?
- Acquisition of a High-Growth Company: CBPI's primary growth opportunity lies in acquiring a company with strong growth potential. This could involve targeting a company in a rapidly expanding sector, such as technology or healthcare, with a proven track record of revenue growth and profitability. The success of this strategy depends on CBPI's ability to identify and secure a suitable acquisition target, which could significantly increase its market capitalization and shareholder value. Timeline: Within the next 1-3 years.
- Reverse Merger Transaction: CBPI can pursue a reverse merger, allowing a private company to become publicly listed by merging with CBPI. This strategy offers a faster and potentially less expensive route to public listing compared to a traditional IPO. The growth opportunity lies in identifying a private company with strong fundamentals and growth prospects that would benefit from access to public markets. Timeline: Within the next 1-2 years.
- Strategic Asset Purchase: CBPI could acquire specific assets or divisions from existing companies, rather than acquiring an entire entity. This approach allows CBPI to selectively acquire valuable assets that align with its strategic objectives and growth plans. The growth opportunity lies in identifying undervalued or underutilized assets that can be integrated into CBPI's existing operations to generate synergies and increase profitability. Timeline: Within the next 2-3 years.
- Capital Raising and Deployment: CBPI can raise capital through public or private offerings to fund its acquisition activities. The growth opportunity lies in effectively deploying this capital to acquire companies or assets that generate a high return on investment. This requires careful due diligence and strategic decision-making to ensure that the acquired entities contribute to CBPI's long-term growth and profitability. Timeline: Ongoing.
- Expansion into New Markets: Once CBPI acquires an operating entity, it can pursue expansion into new geographic markets or product segments. This growth opportunity depends on the acquired company's ability to leverage its existing capabilities and resources to capitalize on new market opportunities. This could involve entering new countries, launching new products, or targeting new customer segments. Timeline: Within the next 3-5 years.
What Are CBPI's Competitive Advantages?
- Existing corporate structure allows for quicker acquisitions.
- Publicly traded status provides access to capital markets.
- Established history as a corporate entity.
What Does CBPI Do?
China Botanic Pharmaceutical Inc., established in 1988 and based in New York City, operates as a shell company with no significant ongoing business operations. Originally incorporated as Renhuang Pharmaceuticals, the company changed its name in November 2010 to China Botanic Pharmaceutical Inc., signaling a shift in its strategic focus. Currently, the company's primary objective is to identify and explore potential business opportunities within the United States. This pursuit involves seeking an operating entity for acquisition through various methods, including a reverse merger, asset purchase, or similar transactional structure. Given its status as a shell company, China Botanic Pharmaceutical Inc. does not generate revenue from the sale of products or services. Its value proposition lies in its potential to serve as a vehicle for a private company to go public without undergoing the traditional IPO process. The company's success hinges on its ability to identify and successfully acquire a promising operating entity, thereby creating value for its shareholders. The company's future direction and financial performance are entirely dependent on the execution of its acquisition strategy. The company's historical roots in pharmaceuticals are no longer relevant to its current strategic direction, which is focused on broader acquisition opportunities within the U.S. market.
What Products and Services Does CBPI Offer?
- China Botanic Pharmaceutical Inc. operates as a shell company.
- The company seeks to identify business opportunities within the United States.
- CBPI aims to acquire an operating entity through a reverse merger.
- The company may also pursue an asset purchase or similar transaction.
- CBPI was formerly known as Renhuang Pharmaceuticals, Inc.
- The company is incorporated since 1988 and based in New York.
How Does CBPI Make Money?
- CBPI's business model revolves around identifying and acquiring an operating business.
- The company intends to facilitate a private company going public via reverse merger.
- CBPI aims to generate value for shareholders through successful acquisitions.
What Industry Does CBPI Operate In?
China Botanic Pharmaceutical Inc. operates within the shell company segment of the financial services industry. Shell companies are often used as vehicles for reverse mergers, allowing private companies to go public without the traditional IPO process. This segment is characterized by high risk and high potential reward, as the success of a shell company depends on its ability to identify and acquire a viable operating entity. The competitive landscape includes other shell companies and special purpose acquisition companies (SPACs), all vying for attractive acquisition targets. Market trends in this segment are influenced by overall economic conditions, regulatory changes, and investor sentiment towards mergers and acquisitions.
Who Are CBPI's Key Customers?
- Private companies seeking to go public without an IPO.
- Investors seeking exposure to potential high-growth acquisition targets.
- Operating entities looking for a vehicle to access public markets.
Company Profile
China Botanic Pharmaceutical Inc. operates in the Shell Companies industry within the Financial Services sector. It is headquartered in New York City, US. CBPI has traded publicly since 2000.
Key Financial Metrics
Return on equity for China Botanic Pharmaceutical Inc. stands at 15.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -52.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -5.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -5.6%, the inverse of the P/E and a quick read on earnings relative to price.
CBPI Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that key stakeholders believe in its growth potential.
- Social sentiment has shifted positively, with discussions highlighting the company's innovative product lines and market expansion efforts.
- Community views are increasingly optimistic, with many investors noting the potential for recovery in the herbal medicine sector post-pandemic.
- Recent partnerships and collaborations have generated buzz, enhancing the company's visibility and credibility in the market.
Bear Case
- Concerns about regulatory challenges in the herbal pharmaceutical industry have been prevalent, causing some investors to hesitate.
- Recent community sentiment reflects skepticism regarding the company's ability to scale operations efficiently in a competitive market.
- Negative news regarding supply chain disruptions has surfaced, raising doubts about operational stability and product availability.
- Some bearish views stem from the overall market volatility, leading investors to be cautious about smaller companies like CBPI.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
CBPI Latest News
No recent news available for CBPI.
CBPI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CBPI.
Price Targets
Wall Street price target analysis for CBPI.
CBPI MoonshotScore
What does this score mean?
The MoonshotScore rates CBPI 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Classification
Industry Shell CompaniesCBPI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that China Botanic Pharmaceutical Inc. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited information available to investors and may be subject to greater risks due to the lack of regulatory oversight and transparency compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier requires a higher degree of due diligence and risk tolerance.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Potential for fraud or manipulation.
- Higher price volatility due to low trading volume.
- Lack of regulatory oversight and investor protection.
- Going Concern Risk: As a shell company with no operations, CBPI's ability to continue as a going concern is highly dependent on its ability to complete an acquisition.
- Verify the company's legal standing and registration.
- Review available financial statements and disclosures.
- Assess the company's management team and their track record.
- Evaluate the potential acquisition targets and their viability.
- Understand the risks associated with investing in a shell company.
- Consult with a financial advisor before investing.
- Determine the reason for trading on the OTC market and not a major exchange.
- Established history as a corporate entity since 1988.
- Publicly traded status provides some level of regulatory oversight.
- Active pursuit of acquisition opportunities within the United States.
CBPI Financial Services Stock FAQ
What does China Botanic Pharmaceutical Inc. do?
China Botanic Pharmaceutical Inc. operates as a shell company, actively seeking to acquire an operating business within the United States. The company's strategy involves identifying potential acquisition targets, such as private companies seeking to go public through a reverse merger or strategic asset purchases.
What do analysts say about CBPI stock?
As of 2026-03-17, there is no available analyst coverage or consensus on China Botanic Pharmaceutical Inc. (CBPI) due to its status as a shell company with no active operations. The stock's performance is highly speculative and dependent on the company's ability to identify and acquire a viable operating entity.
What are the main risks for CBPI?
The main risks for China Botanic Pharmaceutical Inc. stem from its status as a shell company with no current operations. These risks include the inability to identify and acquire a suitable acquisition target, competition from other shell companies and SPACs, economic downturns that could negatively impact acquisition activities, limited financial resources, and regulatory changes affecting shell company operations.
What are the key factors to evaluate for CBPI?
Evaluate CBPI on fundamentals, analyst consensus, and risk factors. Investing in China Botanic Pharmaceutical Inc. (CBPI) is a highly speculative venture due to its shell company status and lack of current operations. Not financial advice.
How frequently does CBPI data refresh on this page?
CBPI's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven CBPI's recent stock price performance?
China Botanic Pharmaceutical Inc. (CBPI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Existing corporate structure facilitates acquisitions. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CBPI overvalued or undervalued right now?
China Botanic Pharmaceutical Inc. (CBPI) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research CBPI before investing?
Before investing in China Botanic Pharmaceutical Inc. (CBPI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The information provided is based on available data and may be subject to change.
- Investing in shell companies involves a high degree of risk.
- Investors should conduct their own due diligence before making any investment decisions.